Metformin and lung cancer
نویسنده
چکیده
Metformin, a commonly used anti-diabetic drug has emerged as a potential anti-cancer drug. Over the last few years, a mass of epidemiologic, outcomes and preclinical data has emerged demonstratic the potential clinical relevance and the mechanistic basis of the anti-cancer activity of this well tolerated drug in lung cancer. This review article summarizes this evidence that supports the trial of this drug in in lung cancer. Yendamuri S. Metformin and lung cancer. J Clin Sci Res 2014;3:26-32. Corresponding author: Sai Yendamuri . Associate Professor, Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York. e-mail: [email protected] Received: 19 September, 2013. Metformin and lung cancer Yendamuri
منابع مشابه
Metformin use and survival from lung cancer: A population-based cohort study.
Preclinical evidence suggests that metformin, a widely prescribed anti-diabetic drug, may inhibit lung cancer progression. We investigated whether metformin use was associated with decreased risk of cancer-specific mortality in lung cancer patients. This study included newly diagnosed lung cancer patients (identified from English National Cancer Data Repository, 1998-2009) with type 2 diabetes ...
متن کاملMetformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. (-)-Epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, is widely studied as a cancer chemopreventive agent with potential anti-cancer effects. The NF-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway is considered to mediate cellular resistance to EGCG. Metformin, a classical antidiabe...
متن کاملComment on: Smiechowski et al. The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes. Diabetes Care 2013;36:124–129
One cohort study recently published in Diabetes Care about the association between metformin use and lung cancer risk was interesting. Smiechowski et al. (1) have reported that metformin use cannot correlate with decreased risk of lung cancer in patients with type 2 diabetes (rate ratio 0.94; 95% CI 0.76–1.17). However, onewell-designed meta-analysis byNoto et al. (2) has shown that metformin u...
متن کاملMetformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.
BACKGROUND Published data suggest that diabetes influences survival of patients with lung cancer. The anti-cancer effect of metformin confounds this association. We sought to study the association of diabetes and metformin with survival in patients undergoing resection of stage I non-small cell lung cancer (NSCLC). METHODS Pathologic stage I NSCLC patients undergoing anatomic resection from 2...
متن کاملThe Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes
OBJECTIVE Observational studies have associated metformin use with a decreased risk of lung cancer incidence in patients with type 2 diabetes, but the studies had important methodological shortcomings. The objective of this study was to determine whether metformin use is associated with a decreased risk of lung cancer in patients with type 2 diabetes, while avoiding previous biases. RESEARCH ...
متن کامل